China
Africa
Explore chapters and articles related to this topic
The Volatilome in Metabolomics
Published in Raquel Cumeras, Xavier Correig, Volatile organic compound analysis in biomedical diagnosis applications, 2018
Raquel Cumeras, Xavier Correig
Induced (exogenous) human volatiles are due to non-harmful external conditions. Those will include the resulting VOCs from the exposure to:drugs (Cumeras et al., 2013) – studied in pharmacometabolomics;environment (excluding pollutants) (Haitham et al., 2013);exposure to ionizing radiation (Menon et al., 2016) – studied in radiation metabolomics;microbials (excluding pathogens) (Petrof et al., 2013) – studied in microbiome; andnutrition (Gibney et al., 2005) – studied in foodomics.
Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics
Published in Expert Opinion on Drug Discovery, 2018
W. J. van den Brink, T. Hankemeier, P. H. van der Graaf, E. C. M. de Lange
Clearly, there is a need to improve the current methodologies within CNS drug development. Two promising methods in this regard are pharmacokinetic/pharmacodynamic (PK/PD) modeling and pharmacometabolomics [10–12]. PK/PD modeling allows to ‘characterize and predict the time course of drug effects under (patho)physiological conditions’ [13]. Pharmacometabolomics involves the ‘determination of the metabolic state to define signatures before and after drug exposure that might inform treatment outcomes’ [14]. This review discusses how translational CNS drug development can be improved by the integrated application of PK/PD modeling and pharmacometabolomics. An overview will be provided of the role of both fields in translational CNS drug development, after which the opportunities and challenges of an integrated approach will be discussed.
The applications of metabolomics in the molecular diagnostics of cancer
Published in Expert Review of Molecular Diagnostics, 2019
Pro Kit Cheung, Man Hin Ma, Hing Fung Tse, Ka Fai Yeung, Hin Fung Tsang, Man Kee Maggie Chu, Chau Ming Kan, William Chi Shing Cho, Lawrence Bo Wah Ng, Lawrence Wing Chi Chan, Sze Chuen Cesar Wong
Metabolomics technology has a huge potential of its application in precision medicine, by which patients can be treated according to the underlying molecular abnormalities with the aid of metabolic profiling and phenotyping. Another application is that the drug response can be predicted by metabolomics, also known as pharmacometabolomics. For instance, it is applied in organ transplantation to optimize the dose based on MS monitoring of immunosuppressant drugs and their metabolites [11]. Patients are also stratified for the prediction of disease susceptibility and treated with the drug with therapeutic outcomes of clinical drugs by correlating the baseline metabolic profiles of patients with their responses [2].